PerkinElmer, Inc. (PKI)

NYSE: PKI · IEX Real-Time Price · USD
139.30
+2.01 (1.46%)
Dec 7, 2022 4:03 PM EST - Market closed
1.46%
Market Cap 17.34B
Revenue (ttm) 4.57B
Net Income (ttm) 631.71M
Shares Out 126.16M
EPS (ttm) 5.13
PE Ratio 27.15
Forward PE 21.83
Dividend $0.28 (0.20%)
Ex-Dividend Date Jan 19, 2023
Volume 663,809
Open 137.95
Previous Close 137.29
Day's Range 137.95 - 141
52-Week Range 113.46 - 203.16
Beta 1.15
Analysts Buy
Price Target 160.69 (+15.4%)
Earnings Date Nov 8, 2022

About PKI

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technol... [Read more]

Industry Life Sciences Tools & Services
Founded 1937
CEO Prahlad Singh
Employees 16,000
Stock Exchange NYSE
Ticker Symbol PKI
Full Company Profile

Financial Performance

In 2021, PerkinElmer's revenue was $5.07 billion, an increase of 33.95% compared to the previous year's $3.78 billion. Earnings were $943.16 million, an increase of 29.57%.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for PKI stock is "Buy." The 12-month stock price forecast is 160.69, which is an increase of 15.36% from the latest price.

Price Target
$160.69
(15.36% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.

1 week ago - Zacks Investment Research

PerkinElmer's (PKI) New Viral Vector Assays to Boost Workflows

PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.

2 weeks ago - Zacks Investment Research

PerkinElmer Helps Accelerate Gene Therapy Research with Industry-First Ready-to-Use Viral Vector Assays

WALTHAM, Mass.--( BUSINESS WIRE )--PerkinElmer, Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today launched ready-to-use Adeno-associated Virus Vectors (AAV) Detectio...

2 weeks ago - Business Wire

PerkinElmer's (PKI) New Marketing Approval to Aid Infant Health

PerkinElmer's (PKI) EONIS SCID-SMA assay kit is expected to enable early SMA and SCID screening in newborns following the FDA's approval.

3 weeks ago - Zacks Investment Research

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screenin...

WALTHAM, Mass.--( BUSINESS WIRE )--PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the U.S. Food and Drug Administration (FDA) has autho...

3 weeks ago - Business Wire

PerkinElmer to Present at 2022 Stifel Healthcare Conference

WALTHAM, Mass.

3 weeks ago - Business Wire

PerkinElmer (PKI) Q3 Earnings Top, Revenues Decline Y/Y

PerkinElmer's (PKI) third-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, which was more than offset by lower COVID-related sales.

4 weeks ago - Zacks Investment Research

PerkinElmer (PKI) Q3 Earnings Surpass Estimates

PerkinElmer (PKI) delivered earnings and revenue surprises of 2.03% and 30.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

PerkinElmer (PKI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

EPIC SCIENCES EXPANDS EXECUTIVE TEAM AND WELCOMES NEW CHIEF FINANCIAL OFFICER IN PREPARATION FOR RAPID GROWTH

Bill Kullback Brings Proven Track Record of Scaling Companies for Successful Outcomes SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -- Epic Sciences, Inc. ("Epic" or "Epic Sciences"), a privately held diagnosti...

1 month ago - PRNewsWire

Will PerkinElmer (PKI) Beat Estimates Again in Its Next Earnings Report?

PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 month ago - Zacks Investment Research

PerkinElmer Board Declares Quarterly Dividend

WALTHAM, Mass.

1 month ago - Business Wire

Gutsy Investors Load Up On 9 Stocks In Surprise $1.3 Trillion Rally

Many S&P 500 investors are still hiding from the bear. But some are stepping in front of what they think is a moneymaking moment.

1 month ago - Investors Business Daily

PerkinElmer Sweetens Its Outlook And Shares Surge, But There's Still One Hitch

PerkinElmer said Monday it expects organic sales and adjusted profit to top its previous third-quarter expectations, and PKI stock jumped. The post PerkinElmer Sweetens Its Outlook And Shares Surge, But...

1 month ago - Investors Business Daily

3 Stocks to Watch on Rising Demand for Scientific Instruments

The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), Waters (WAT) and PerkinElmer (PKI) are gaining from strong life science, pharmaceutical and academic end-market demand...

Other symbols: MTDWAT
1 month ago - Zacks Investment Research

PerkinElmer's (PKI) New Benchtop Platform to Boost Workflows

PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.

2 months ago - Zacks Investment Research

PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca® PLX Image Cytometry System, a first-of-its-kin...

2 months ago - Business Wire

PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance

PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.

2 months ago - Zacks Investment Research

PerkinElmer's Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculo...

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer's (NYSE: PKI) Oxford Immunotec today announced the U.S. Food and Drug Administration (FDA) has approved the use of the T-Cell Select™ reagent kit for the aut...

2 months ago - Business Wire

U.S. Market Faces Worst Meltdown Since 2020: Here's Why

Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.

Other symbols: AVTRPACB
2 months ago - Zacks Investment Research

PerkinElmer (PKI) Down 11.6% Since Last Earnings Report: Can It Rebound?

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research